Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies, Inc. (Nasdaq: BSGM) is a Minneapolis-based medical technology company focused on the development and commercialization of advanced digital signal processing technology. The company aims to revolutionize the $3 billion electrophysiology (EP) market with its flagship product, the PURE EP™ Platform. This FDA-cleared, non-invasive class II device combines innovative hardware and software to provide unparalleled clarity and precision in visualizing intracardiac signals. The technology facilitates highly targeted cardiac ablation procedures, improving procedural efficiency and patient outcomes.
BioSig's commitment to addressing healthcare's critical priorities—saving time, reducing costs, and saving lives—is reflected in its collaborative efforts with leading medical centers, including the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute. The PURE EP™ Platform's Near-Field Tracking (NFT) algorithm, introduced in Q4 2023, has already demonstrated a significant reduction in ablation time by approximately 66%, highlighting its potential to enhance clinical procedures.
Despite recent challenges, including workforce reductions and strategic shifts, BioSig remains focused on expanding its product's adoption and exploring new market opportunities. The company recently appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies and continues to work on potential commercialization opportunities within the AI space.
Under the leadership of a new CEO and a reconstituted Board of Directors, BioSig is committed to restoring and creating lasting shareholder value. The company has also addressed compliance issues with the Nasdaq Hearings Panel, further solidifying its position in the marketplace.
For more information and the latest updates, visit the SEC's website.
BioSig Technologies (NASDAQ: BSGM) will showcase its PURE EP System at the 26th Annual International Atrial Fibrillation Symposium on January 29, 2021. G. Joseph Gallinghouse, M.D., from the Texas Cardiac Arrhythmia Institute, will present clinical observations from over 470 patient cases. The event is accessible virtually, offering free registration, and aims to highlight advancements in atrial fibrillation technology. Kenneth L. Londoner, CEO of BioSig, expresses gratitude for the opportunity to engage with a broader audience this year.
BioSig Technologies, a medical technology firm, has been featured in EP Lab Digest for its PURE EP™ System, addressing challenges in electrophysiology (EP). The article emphasizes issues like signal loss and inadequate signal-to-noise ratios in EP labs. The PURE EP™ System's advanced technology helps improve signal fidelity, as demonstrated by recent research where 85% of signals were rated as equivalent or superior. CEO Kenneth Londoner noted the importance of this recognition and plans for increased physician collaborations in 2021.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced a partnership with Vuzix® Corporation (NASDAQ: VUZI) to enhance its PURE EP™ System. The collaboration involves deploying Vuzix’s M400 Smart Glasses for remote servicing, facilitating installations and training during COVID-19 restrictions. This initiative aims to improve efficiency and reduce costs for technicians by enabling remote support. The M400 Smart Glasses utilize Qualcomm's Snapdragon XR1 platform, offering advanced features for various applications, potentially elevating the standard of care in the electrophysiology market.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced the installation and first patient cases of its PURE EP(tm) System at Memorial Hospital in South Bend, Indiana. The evaluation is led by cardiologists Vinod Chauhan, M.D., and Deepak Gaba, M.D. To date, over 450 cases have been conducted across seven clinical sites. The company has initiated commercial sales of the system, emphasizing the importance of addressing heart rhythm disorders, especially amid the COVID-19 pandemic. BioSig continues to expand its clinical operations in 2021.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced that Kenneth L. Londoner, Chairman and CEO, will present at the Sidoti Winter 2021 Investor Conference on January 13, 2021, at 2:30 PM ET. The presentation will cover company highlights and achievements, including over 410 patient procedures with the PURE EP™ System conducted by 32 electrophysiologists in seven U.S. clinical sites. Interested parties can register for the presentation and one-on-one meetings through provided links.
BioSig Technologies (NASDAQ: BSGM) has announced a collaboration with the University of Minnesota to develop therapies for autonomic nervous system diseases through its NeuroClear Technologies division. This agreement aims to create new hardware, software, and algorithmic solutions for these conditions. The R&D program is expected to commence in Q4 2020 and will be led by esteemed professionals from the university. The partnership signifies a strategic move to enhance BioSig's bioelectronic medicine innovations, potentially fueling product development and FDA approval.
BioSig Technologies announces a significant commercial expansion through the sale of three PURE EP™ Systems to St. David's HealthCare in Austin, Texas. This marks BioSig's first commercial sale, aimed at expanding its installed base nationwide. The PURE EP™ System has already been utilized in over 410 patient procedures across six hospital sites, demonstrating its traction in the electrophysiology market. The company emphasizes the importance of this sale as it strengthens their relationship with St. David’s Medical Center, a recognized leader in healthcare quality.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced that Kenneth L. Londoner, Chairman and CEO, will present at the 13th Annual LD Micro Main Event Conference on December 14, 2020, at 10:20 AM ET. The presentation will cover company highlights, showcasing the PURE EP™ System, which has been used in over 400 procedures by more than 25 electrophysiologists across six U.S. clinical sites. BioSig is focused on improving ECG and intra-cardiac signal fidelity through its proprietary biomedical signal processing platform.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced its PURE EP™ System is installed in six medical centers, facilitating over 350 clinical cases managed by 25 electrophysiologists. The company's evaluation installations are increasing, strengthening its commercial framework for 2021. CEO Kenneth L. Londoner will present at the Benzinga Global Small Cap Conference on December 8, 2020, detailing operational highlights and commercialization goals. The PURE EP™ System enhances ECG and intra-cardiac signal analysis, contributing to advancements in electrophysiology practices.
BioSig Technologies announced its PURE EP™ System will be featured in live cases at EPLive 2020 on December 3-4, 2020, showcasing advancements in treating complex cardiac arrhythmias. The event, hosted at the Texas Cardiac Arrhythmia Institute, will involve 21 live and 13 recorded cases, aimed at educating electrophysiologists and cardiologists. Over 350 cases using the PURE EP™ System have been completed, indicating its growing significance in the field. The company expresses gratitude for the support received during this challenging time due to the pandemic.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
What does BioSig Technologies, Inc. do?
What is the PURE EP™ Platform?
Who are BioSig's collaborators?
What recent achievements has BioSig made?
How is BioSig addressing its financial and operational challenges?
What are BioSig's future plans?
How does the NFT algorithm benefit clinical procedures?
Is BioSig publicly traded?
What steps has BioSig taken to comply with Nasdaq requirements?
Where can I find more information about BioSig?
